Business
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.471 Royalty Revenue
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.471 \nRoyalty Revenue Increased 43% YOY to $99.6 million\nReiterating 2023 Revenue Guidance of $815-$845 million, Representing 23-28% YOY Growth; EBITDA of $415-$440 million, Representing >30% YOY Growth1 \nSAN DIEGO, May 9, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today reported its financial and operating results for the first quarter ended March 31, 2023 and provided an update on its recent corporate activities and outlook.\n\"We executed to our plan in the first quarter with total year-over-year revenue growth of 38% to $162 million. We expect strong quarter-over-quarter revenue growth for the remainder of the year, driven largely by royalties from continued uptake of Darzalex® SC and Phesgo®, milestone revenue, and sales of our commercial products,\" said Dr. Helen Torley, president and chief executive officer of Halozyme. \"We are looking forward to the expansion of our commercialized partner products utilizing ENHANZE® with potential regulatory approvals for SC efgartigimod for generalized myasthenia gravis and for SC atezolizumab, later this year. We are on track to achieve our financial guidance and operational goals for 2023. Our differentiated ENHANZE® and auto-injector technologies position us well to execute on our growth goals and drive long-term value for our stakeholders.\"\nRecent Partner Highlights: \nIn April 2023, Takeda announced that the U.S. Food and Drug Administration (\"FDA\") approved a supplemental Biologics License Application (\"sBLA\") to expand the use of HYQVIA® to treat primary immunodeficiency in children.In March 2023, BMS initiated a Phase 3 trial to demonstrate the drug exposure levels of nivolumab and relatlimab fixed-dose combination with ENHANZE® is not inferior to IV administration in participants with previously untreated metastatic or unresectable melanoma (RELATIVITY-127).In January 2023, Roche announced the FDA accepted the Biologics License Application (\"BLA\") for SC atezolizumab with ENHANZE® with a PDUFA date of September 15, 2023.In January 2023, argenx announced that the FDA extended the PDUFA date for SC efgartigimod with ENHANZE® for generalized myasthenia gravis to June 20, 2023.Recent Corporate Highlights:...